Cholesterol has a public-relations problem. This week, on The Integrative Cardiologist, I want to fix it: first with a walking tour of the whole map, then with three Tuesday articles on how food, exercise, medication, and supplements change the traffic.
Cholesterol is often discussed as though it were a poison sloshing through the bloodstream. It is not.
Every cell in the body needs cholesterol to build its outer membrane. Your body uses it to make hormones such as estrogen and testosterone, to produce vitamin D, and to manufacture bile acids — the fluid the liver releases into the intestine to help digest fat.
The problem is not cholesterol’s existence. The problem is exposure: how many cholesterol-carrying particles are circulating, how long they remain in the bloodstream, and whether they enter and become trapped inside artery walls.
Last week’s article on the five calcium scores was about what we can see after years of arterial wear, inflammation, and repair. This article is about the traffic that comes first: the particles in the blood, the factors that make them more likely to accumulate in artery walls, and the levers that can reduce that burden over time.
Where “Good” and “Bad” Cholesterol Came From
Most people arrive at a cholesterol discussion with the same basic vocabulary: LDL is “bad” cholesterol and HDL is “good” cholesterol.
Those labels did not come from marketing. They grew out of decades of observation, including the Framingham Heart Study. In 1948, the US Public Health Service began following roughly 5,200 adults in Framingham, Massachusetts, to understand why heart attacks and strokes occurred in some people and not others. Their children later joined the study. Then their grandchildren. It became one of the most influential long-term records in cardiovascular medicine.
By the 1970s, Framingham investigators had shown that higher LDL cholesterol tracked with greater coronary risk, while higher HDL cholesterol tracked with lower risk. The shorthand stuck.
LDL became the “bad” one. HDL became the “good” one.
But the labels were always incomplete.
LDL is not “bad” because the body made a mistake by producing it. LDL is a normal transport particle. It carries cholesterol through the bloodstream for ordinary biological purposes. HDL participates in cholesterol transport as well, but a high HDL cholesterol number is not a guarantee of protection, and medications that raise HDL-C have not reliably reduced cardiovascular events.
The modern view is more useful.
Atherosclerosis is not passive grease collecting in a pipe. The artery wall is alive. Its inner lining — the endothelium — responds to blood pressure, smoking, diabetes, kidney disease, inflammation, genetics, and decades of metabolic stress.
But the essential first step is that particles carrying ApoB — including LDL, VLDL remnants, IDL, and Lp(a) — enter the artery wall and become retained there. Once trapped, they can be modified, recognized by the immune system, and set off a chronic inflammatory process that becomes plaque.
So LDL is not a moral villain. It is a normal particle that becomes harmful when too many ApoB-containing particles circulate for too many years and repeatedly gain access to the artery wall.
The artery wall matters, and so does the traffic. Atherosclerosis develops when ApoB-containing particles repeatedly enter and remain in an arterial environment made more vulnerable by high blood pressure, smoking, diabetes, kidney disease, inflammation, genetics, and time.
Cholesterol Does Not Travel Freely
Fat and cholesterol do not dissolve well in blood. So the body packages them into tiny particles called lipoproteins — bundles of fat and protein that travel through the circulation.
Some carry fat absorbed from a meal. Some carry triglycerides made by the liver. Some carry cholesterol to tissues. Some participate in moving excess cholesterol back toward the liver.
Each particle has a job, a route, and an identifying protein on its surface — an apolipoprotein — that helps determine where it goes and how the body handles it.
The metaphor has limits, but it is useful to think of these particles as vehicles in a transit system. The key prevention question is not whether any one vehicle is “evil.” It is whether there are too many artery-capable vehicles on the road, for too long.
The Fleet — At a Glance
There are six particles worth knowing.
Chylomicrons are large particles made by the intestine after a meal. They carry dietary fat from the gut into circulation. The intact particles are generally cleared quickly, although their remnants can matter when triglycerides are persistently elevated.
VLDL, or very-low-density lipoprotein, is made by the liver. It carries triglycerides to muscle and fat tissue. As VLDL unloads triglyceride, it becomes smaller and more cholesterol-rich. Those remnant particles can enter the artery wall.
IDL, or intermediate-density lipoprotein, is a short-lived middle stage in the transition from VLDL to LDL. It is also an ApoB-containing particle that can contribute to atherosclerosis.
LDL, or low-density lipoprotein, is the most familiar cholesterol-carrying particle. It delivers cholesterol to tissues throughout the body. When LDL particle burden is too high, it becomes a major driver of plaque formation.
HDL, or high-density lipoprotein, participates in cholesterol transport back toward the liver and has other biologic functions. But a higher HDL cholesterol number does not automatically mean lower cardiovascular risk.
Lp(a) is an LDL-like particle with an additional protein attached. It is largely inherited, can independently raise cardiovascular risk, and is especially prone to retention in the artery wall. It is worth measuring at least once in adulthood.
The Tag That Matters: ApoB
Every VLDL, remnant particle, IDL, LDL particle, and Lp(a) particle carries one ApoB tag on its surface.
That makes ApoB useful. Measuring ApoB gives an estimate of how many potentially artery-entering particles are circulating in your blood.
Your routine lipid panel reports the amount of cholesterol inside LDL particles — your LDL cholesterol, or LDL-C. ApoB answers a different question: how many ApoB-containing particles are actually circulating?
Those are not always the same story.
Two people can have the same LDL cholesterol level but very different ApoB levels. One person may have fewer, cholesterol-rich LDL particles. The other may have many more particles, each carrying less cholesterol. The second person has more opportunities, day after day and year after year, for particles to enter and remain in the artery wall.
This is especially relevant when triglycerides are elevated, insulin resistance is present, diabetes or metabolic syndrome is part of the picture, or LDL-C and the rest of the metabolic story do not seem to match.
LDL cholesterol remains an important number and a central treatment target. But ApoB can add useful information, particularly when the situation is metabolically complicated.
If ApoB is not available, non-HDL cholesterol — total cholesterol minus HDL cholesterol — is present on almost every standard lipid panel and is a helpful, inexpensive surrogate for the cholesterol carried by atherogenic particles.
The practical takeaway is simple: the cholesterol inside each particle matters, but the number of ApoB-containing particles tells us how many chances there are for cholesterol-carrying particles to enter and remain in the artery wall.
Two Main Levers
Most interventions that reduce LDL-related risk work through one or both of two pathways.
First: reduce the number of ApoB-containing particles in circulation. That can involve improving diet quality, reducing excess saturated fat, lowering refined-carbohydrate intake when triglycerides are elevated, losing weight when appropriate, improving insulin sensitivity, and using medications that reduce hepatic cholesterol production or intestinal cholesterol absorption.
Second: improve clearance of LDL from the bloodstream. The liver removes LDL through LDL receptors. Think of them as depot stations. The more receptors available and functioning, the faster LDL can be removed from circulation.
Statins increase LDL-receptor activity. PCSK9-targeting therapies help prevent LDL receptors from being degraded. Other interventions can support the same overall clearance pathway.
The metaphor is imperfect, but it is useful: less atherogenic traffic entering circulation and better traffic removal both reduce lifetime exposure of the artery wall to ApoB-containing particles.
Where Things Go Wrong
Some conditions leave LDL particles circulating longer than they should. Genetics, hypothyroidism, kidney disease, certain medications, and a diet high in saturated fat can all contribute.
Other factors increase the number of triglyceride-rich particles the liver produces. Insulin resistance, diabetes, central weight gain, alcohol excess, and diets high in refined starches and added sugars can raise triglycerides and worsen the overall metabolic pattern.
Then there are inherited conditions that set a high baseline regardless of how well someone eats or exercises. Familial hypercholesterolemia and elevated Lp(a) are two important examples. They are why some people with excellent lifestyles still need medication.
That is not a failure of effort. It is biology.
What Diet and Exercise Can Change
Food does not act on cholesterol through one pathway. Some choices affect cholesterol absorption. Some affect bile recycling. Some influence triglyceride-rich particles, insulin resistance, body weight, or the liver’s ability to clear LDL.
The most reliable dietary foundation is familiar: more vegetables, fruit, beans, lentils, intact whole grains, nuts, seeds, and minimally processed foods; more unsaturated fats from olive oil, nuts, seeds, avocado, and fish; and less reliance on processed meats, sugary drinks, refined carbohydrates, and foods high in saturated fat.
Soluble fiber from oats, beans, psyllium, barley, lentils, apples, berries, chia, and flax can help lower LDL cholesterol. It binds bile acids in the intestine, which encourages the liver to draw on cholesterol and increase LDL-receptor activity. Psyllium and oat beta-glucan are among the most useful and low-risk non-prescription tools for modest LDL lowering.
Replacing saturated fat with unsaturated fat also matters. Olive oil, nuts, seeds, avocado, and fish generally improve LDL-related measures when they replace butter, fatty or processed meats, and other major sources of saturated fat. The substitution is what matters. Adding olive oil to an otherwise highly processed diet is not the same intervention.
Refined carbohydrates and sugary drinks often show up first in the triglyceride number. In people with insulin resistance, diabetes, central weight gain, or a genetic tendency toward high triglycerides, a pattern high in sweet drinks, sweets, refined flour, and heavily processed starches can worsen triglycerides and metabolic health.
Fatty fish is a good protein choice, especially when it replaces processed or fatty meat. For people with very high triglycerides, prescription omega-3 therapy may be appropriate, but a prescription product is not interchangeable with an over-the-counter fish-oil supplement or a couple of servings of salmon each week.
Exercise provides benefits that food alone cannot. Regular movement improves blood pressure, insulin sensitivity, triglyceride clearance, fitness, body composition, sleep, and long-term cardiovascular resilience. A practical goal remains at least 150 minutes a week of moderate-intensity aerobic activity, plus resistance training at least twice weekly.
Fasting is more modestly useful than the internet suggests. A comfortable overnight eating window helps some people reduce late-night eating, improve weight regulation, or improve blood sugar. It is not required for cardiovascular prevention, and whether it improves a lipid panel depends heavily on the quality and quantity of food inside the eating window.
Part 2 will cover these diet, exercise, and fasting questions with specific targets, references, and honest caveats.
What Medications Actually Do
When diet, exercise, and time are not enough — because of genetics, existing plaque, diabetes, chronic kidney disease, familial hypercholesterolemia, or a high lifetime cardiovascular risk — medications provide additional ways to lower ApoB-containing particle burden.
Statins reduce the liver’s own cholesterol production. In response, the liver increases LDL-receptor activity and removes more LDL from the bloodstream. They are the most studied cholesterol-lowering medicines in cardiovascular prevention and reduce heart attack, stroke, and cardiovascular death in appropriately selected patients.
Ezetimibe reduces cholesterol absorption in the intestine. It is often used with a statin when additional LDL lowering is needed or when a person cannot tolerate higher statin doses.
PCSK9-targeting therapies include injectable antibodies given every few weeks and inclisiran, an siRNA therapy given twice yearly after its initial doses. These treatments help preserve LDL receptors and can produce major LDL reductions. They are commonly considered for people with established cardiovascular disease, familial hypercholesterolemia, very high LDL despite maximally tolerated therapy, or selected cases of statin intolerance.
Bempedoic acid reduces cholesterol production upstream from where statins work. It can be particularly useful for people who cannot tolerate statins or need additional LDL lowering.
Icosapent ethyl is prescription-strength purified EPA, a specific omega-3 formulation shown to reduce cardiovascular events in selected high-risk patients with elevated triglycerides. It is not the same as an over-the-counter fish-oil supplement.
Starting medication is not a failure of diet. It is another way to reduce the lifetime traffic that damages arteries.
An Honest Word About Supplements
Patients ask about supplements every day. Some are genuinely useful. Some have modest effects. Some are heavily marketed with claims their evidence does not support.
The short version is this: soluble fiber, especially psyllium and oat beta-glucan, is among the most useful low-risk, non-prescription tools for modest LDL lowering.
Plant sterols may provide a small additional LDL reduction for some people. They can be reasonable as an add-on, but they should not be confused with a proven substitute for statins or other medications that reduce cardiovascular events.
Red yeast rice deserves special caution. It may work because some products contain monacolin K, a compound chemically identical to lovastatin. In other words, it can act like a statin because it is, pharmacologically, a statin exposure. Product contents can vary substantially. It can cause muscle symptoms, liver-enzyme abnormalities, medication interactions, and other adverse effects. It deserves medical supervision, not a “natural” free pass.
Berberine is promising but inconsistent across preparations and studies. It can affect blood sugar, may modestly improve lipid measures in some people, and has real potential for medication interactions and gastrointestinal side effects. It is not a substitute for guideline-based therapy when medication is indicated.
Aged garlic extract may have modest effects in some studies, but the results are mixed. Curcumin remains an interesting compound for research, but it should not be presented as a proven cardiovascular-prevention supplement. Niacin, once widely promoted for HDL and cholesterol management, did not improve cardiovascular outcomes when added to statin treatment in major modern trials and produced meaningful side effects.
The central rule for the supplement aisle is simple: a product that changes a laboratory number is not automatically proven to prevent a heart attack or stroke.
Part 3 will cover ten commonly discussed supplements — what they may do, what they probably do not do, and which ones I would generally skip.
What This Means for Your Next Visit
If you take nothing else from this Sunday overview, take these six questions into your next appointment:
Ask whether ApoB would add useful information to your lipid assessment, especially if triglycerides are elevated or you have insulin resistance, diabetes, metabolic syndrome, or a mismatch between LDL-C and your overall risk picture.
Ask for an Lp(a) measurement at least once in adulthood if you have never had one.
Ask whether high-sensitivity CRP, or hsCRP, would add useful information in your case. It is a nonspecific marker of systemic inflammation, not a direct measurement of inflammation inside your arteries, but a persistently elevated level can sometimes help refine cardiovascular risk.
Take blood pressure, waist circumference, physical activity, sleep, blood sugar, and smoking status as seriously as the cholesterol numbers. They are cardiovascular numbers too.
If the decision about medication is unclear, ask whether a coronary artery calcium score would help. CAC is most useful as a decision tool when risk is uncertain — not as routine testing for everyone.
Ask directly whether your current numbers warrant medication and, if you already take medication, whether the dose and treatment plan fit your actual risk rather than simply the laboratory reference range.
The question is not simply, “Is my LDL normal?”
A better question is: “Given my full risk profile, is my lifetime exposure to ApoB-containing particles low enough to protect my arteries over the next twenty to thirty years?”
That is the central framework for this series.
What’s Coming This Week
Tuesday 9/8/26 — Part 1: The Framework
A closer look at the six particles, the ApoB tag, and how to read your own lipid panel through this map. Where each number comes from, what it tells you, and what it cannot tell you.
Tuesday 9/15/26— Part 2: How Diet, Fasting, and Exercise Change the Traffic
Which foods affect which parts of the lipid system. Why exercise matters beyond the scale. Where fasting can help, and where it is oversold.
Tuesday 9/22/26 — Part 3: Medications and Supplements — What the Evidence Actually Supports
A practical tour of the prescriptions that reduce heart attack and stroke risk, plus an evidence-based look at the ten supplements patients ask about most: useful options, modest add-ons, and products I would generally avoid.
If a term in today’s overview raised a question you want answered in greater depth, one of the next three articles will probably address it. If not, reply to the Tuesday emails. Your questions will help shape future posts.
This article is for patient education. It is not a substitute for individualized medical advice. Cholesterol management should be directed by your clinician using validated risk assessment and current guideline-based therapy. Do not start, stop, or change any medication or supplement without discussing it with your healthcare professional.
Sources
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. Lancet. 2013.
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High Density Lipoprotein as a Protective Factor Against Coronary Heart Disease: The Framingham Study. American Journal of Medicine. 1977.
Ross R. Atherosclerosis — An Inflammatory Disease. New England Journal of Medicine. 1999.
Libby P. Inflammation and the Pathogenesis of Atherosclerosis. Vascular Pharmacology. 2024.
Glavinovic T, et al. Physiological Bases for the Superiority of Apolipoprotein B Over LDL Cholesterol and Non-HDL Cholesterol as a Marker of Cardiovascular Risk. Journal of the American Heart Association. 2022.
National Lipid Association. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus.
Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019.
Boden WE, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine. 2011.
Landray MJ, et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine. 2014.
Piercy KL, et al. The Physical Activity Guidelines for Americans. JAMA. 2018.
National Center for Complementary and Integrative Health (NIH). Red Yeast Rice.